Estrategias Combinadas en Inmunoterapia Traslacional
ITC
Universitat Autònoma de Barcelona
Barcelona, EspañaPublikationen in Zusammenarbeit mit Forschern von Universitat Autònoma de Barcelona (11)
2024
2021
-
Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies
Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 882-891
-
CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function
Cancer Immunology Research, Vol. 9, Núm. 12, pp. 1476-1490
2020
-
Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma
Clinical Genitourinary Cancer, Vol. 18, Núm. 6, pp. 452-460
2019
2018
-
SEOM clinical guideline for treatment of kidney cancer (2017)
Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 47-56
2017
-
HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma
OncoTargets and Therapy, Vol. 10, pp. 4635-4643
-
Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial
The Lancet Oncology, Vol. 18, Núm. 5, pp. 672-681
2009
2008
-
Immunotherapy for neurological diseases
Clinical Immunology
2002
-
Deregulated expression of the PCPH proto-oncogene in rat mammary tumors induced with 7, 12-dimethylbenz[a]anthracene
Molecular Carcinogenesis, Vol. 33, Núm. 4, pp. 219-227